1. |
张川, 张伶俐, 林芸竹, 等. 妊娠期用药调查研究的系统评价. 中国药学杂志, 2012, 47(11): 858-862.
|
2. |
Riley LE, Cahill AG, Beigi R, et al. Improving safe and effective use of drugs in pregnancy and lactation: workshop summary. Am J Perinatol, 2017, 34(8): 826-832.
|
3. |
Ramoz LL, Patel-Shori NM. Recent changes in pregnancy and lactation labeling: retirement of risk categories. Pharmacotherapy, 2014, 34(4): 389-395.
|
4. |
张川, 张伶俐, 王晓东, 等. 全球妊娠期用药危险性分级系统的比较分析. 中国药学杂志, 2016, 51(3): 234-238.
|
5. |
FDA. Pregnancy and lactation labeling (drugs) final rule. Available at: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm.
|
6. |
Briggs G. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk (11th Ed). Washington: Lippincott Williams & Wilkins (LWW), 2017.
|
7. |
Schaefer C. Drugs during pregnancy and lactation (Third Ed). Pittsburgh: Academic Press, 2015.
|
8. |
Mitchell AA, Gilboa SM, Werler MM, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol, 2011, 205(1): 51.
|
9. |
Broussard CS, Frey MT, Hernandez-Diaz S, et al. Developing a systematic approach to safer medication use during pregnancy: summary of a centers for disease control and prevention--convened meeting. Am J Obstet Gynecol, 2014, 211(3): 208-214.
|
10. |
Lie L, Shetty V, Gupta K, et al. Exploring the design and role of mobile apps for healthcare providers to find teratogenic information. AMIA Annu Symp Proc, 2017: 1100-1109.
|
11. |
山丹, 译. 孕期与哺乳期用药指南(第二版). 北京: 科学出版社, 2010.
|
12. |
杨慧霞, 段涛. 妊娠期与哺乳期用药(第 7 版). 北京: 人民卫生出版社, 2008.
|
13. |
Hauben M, Aronson JK. Gold standards in pharmacovigilance: the use of definitive anecdotal reports of adverse drug reactions as pure gold and high-grade ore. Drug Saf, 2007, 30(8): 645-655.
|
14. |
Vandenbroucke JP. Thalidomide: an unanticipated adverse effect. JLL Bulletin: Commentaries on the history of treatment evaluation. Available at: http://www.Jameslindlibrary.org/illustrating/articles/thalidomide-an-unanticipated-adverse-effect.
|
15. |
The Joanna Briggs Institute. Joanna Briggs institute reviewers' manual: 2016 edition. Adelaide: The Joanna Briggs Institute, 2016.
|
16. |
Gagnier JJ, Kienle G, Altman DG, et al. The CARE guidelines: consensus-based clinical case report guideline evelopment. J Diet Suppl, 2013, 10(4): 381-390.
|
17. |
杨华, 魏晶, 王嘉仡, 等. 药品不良反应/事件报告评价方法研究. 中国药物警戒, 2009, 6(10): 581-584.
|
18. |
Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses, 2010. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
|
19. |
Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health, 1998, 52(6): 377-384.
|
20. |
Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet, 2011, 157C(3): 175-182.
|
21. |
TERIS. The Teratogen Information System. Available at: http://depts.washington.edu/terisdb/index.html.
|
22. |
Mitchell AA. Studies of drug-induced birth defects. Pharmacoepidemiology (5th ed). Chichester: John Wiley & Sons, 2012: 487-504.
|